MULTIPLE MYELOMA

Adriana Rossi, MD, presents the case of a 75-year-old woman with triple-class refractory multiple myeloma.

Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.

During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

Robert Rifkin, MD, FACP, a hematology oncologist at the Rocky Mountain Cancer Centers, discusses the need for novel treatment options in the relapsed or refractory multiple myeloma population.

Jonathan L. Kaufman, MD, discusses current challenges and unmet needs in the treatment landscape and provides insight into potential improvements in the future of multiple myeloma.

Expert in the management of multiple myeloma Jonathan Kaufman, MD, reviews factors to consider when selecting a treatment regimen for patients with relapsed disease.

Jonathan L. Kaufman, MD, considers updates from the GRIFFIN trial, the MAIA trial, and the PEGASUS study and comments on factors to consider for daratumumab-containing induction regimens.

Key opinion leader in hematology Jonathan L. Kaufman, MD, discusses standard treatment options for newly diagnosed multiple myeloma in transplant and nontransplant treatment settings.

An expert hematologist discusses factors to consider when determining a treatment approach in newly diagnosed multiple myeloma including symptom burden, comorbidities, age, and ECOG performance status.

Jonathan L. Kaufman, MD reviews the case of a 75-year-old man with multiple myeloma by discussing the patient’s presentation, clinical workup, and initial prognosis.

A key opinion leader in hematology, Jonathan Kaufman, MD, provides insight into the case of a 75-year-old man with multiple myeloma and discusses treatment considerations, standard of care therapies, and recent clinical trial updates for the management of multiple myeloma.

The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.

"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."

Thomas G. Martin, MD discussed the case of a patient with newly-diagnosed multiple myeloma during a virtual Targeted Oncology Case-Based Roundtable event.

The FDA has granted approval to the combination of isatuximab added to carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

The paradigm for management of relapsed myeloma is evolving rapidly with a plethora of treatment options based on results of clinical trials. One explosive area of scientific and clinical research is the investigation of chimeric antigen receptor T-cell therapy.

Sagar Lonial, MD, FACP, discusses the management of heavily pretreated relapsed/refractory multiple myeloma and its future.

An expert in multiple myeloma provides insight on the role of belantamab mafodotin in the treatment of heavily pretreated patients with relapsed/refractory multiple myeloma.

Principal investigator Sagar Lonial, MD, FACP, discusses the DREAMM-2 trial and relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, reviews and comments on the treatment options for patients with triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, summarizes the case of a 72-year-old man with heavily pretreated, triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.

A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.

Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.